

# Ruth J Webster

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5958019/ruth-j-webster-publications-by-year.pdf>

**Version:** 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

68  
papers

1,584  
citations

23  
h-index

38  
g-index

79  
ext. papers

1,994  
ext. citations

6.9  
avg, IF

4.45  
L-index

#	Paper	IF	Citations
68	Implementing Single-Pill Combination Therapy for Hypertension: A Scoping Review of Key Health System Requirements in 30 Low- and Middle-Income Countries.. <i>Global Heart</i> , <b>2022</b> , 17, 6	2.9	1
67	The role of digital health for post-surgery care of older patients with hip fracture: A scoping review.. <i>International Journal of Medical Informatics</i> , <b>2022</b> , 160, 104709	5.3	0
66	Pharmacist's time spent: Space for Pharmacy-based Interventions and Consultation Time (SPICE)-an observational time and motion study.. <i>BMJ Open</i> , <b>2022</b> , 12, e055597	3	3
65	An electronic decision support-based complex intervention to improve management of cardiovascular risk in primary health care: a cluster randomised trial (INTEGRATE). <i>Medical Journal of Australia</i> , <b>2021</b> , 214, 420-427	4	1
64	Ultra-low-dose quadruple combination blood pressure-lowering therapy in patients with hypertension: The QUARTET randomized controlled trial protocol. <i>American Heart Journal</i> , <b>2021</b> , 231, 56-67	4.9	3
63	Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial. <i>Lancet, The</i> , <b>2021</b> , 398, 1043-1052	40	17
62	Uncontrolled blood pressure in Australia: a call to action. <i>Medical Journal of Australia</i> , <b>2021</b> ,	4	2
61	Community pharmacist workflow: Space for Pharmacy-based Interventions and Consultation Time study protocol. <i>International Journal of Pharmacy Practice</i> , <b>2020</b> , 28, 441-448	1.7	2
60	Optimising TRIUMPH with 625 mg chlorthalidone - Authors' reply. <i>The Lancet Global Health</i> , <b>2020</b> , 8, e176	13.6	
59	Implementing Fixed Dose Combination Medications for the Prevention and Control of Cardiovascular Diseases. <i>Global Heart</i> , <b>2020</b> , 15, 57	2.9	5
58	Non-Medical prescribing policies: A global scoping review. <i>Health Policy</i> , <b>2020</b> , 124, 721-726	3.2	1
57	Association of Low-Dose Triple Combination Therapy With Therapeutic Inertia and Prescribing Patterns in Patients With Hypertension: A Secondary Analysis of the TRIUMPH Trial. <i>JAMA Cardiology</i> , <b>2020</b> , 5, 1219-1226	16.2	9
56	Implementing cardiovascular disease preventive care guidelines in general practice: an opportunity missed. <i>Medical Journal of Australia</i> , <b>2020</b> , 213, 327-328	4	7
55	Atrial Fibrillation Screen, Management, and Guideline-Recommended Therapy in the Rural Primary Care Setting: A Cross-Sectional Study and Cost-Effectiveness Analysis of eHealth Tools to Support All Stages of Screening. <i>Journal of the American Heart Association</i> , <b>2020</b> , 9, e017080	6	8
54	The 2016 Joint European Prevention Guidelines and the uses of polypills: Time to update the evidence. <i>European Journal of Preventive Cardiology</i> , <b>2020</b> , 27, 437-440	3.9	2
53	Fixed-combination, low-dose, triple-pill antihypertensive medication versus usual care in patients with mild-to-moderate hypertension in Sri Lanka: a within-trial and modelled economic evaluation of the TRIUMPH trial. <i>The Lancet Global Health</i> , <b>2019</b> , 7, e1359-e1366	13.6	12
52	The role of context in implementation research for non-communicable diseases: Answering the 'how-to' dilemma. <i>PLoS ONE</i> , <b>2019</b> , 14, e0214454	3.7	17

51	Reaching cardiovascular prevention guideline targets with a polypill-based approach: a meta-analysis of randomised clinical trials. <i>Heart</i> , <b>2019</b> , 105, 42-48	5.1	22
50	Process evaluation in the field: global learnings from seven implementation research hypertension projects in low-and middle-income countries. <i>BMC Public Health</i> , <b>2019</b> , 19, 953	4.1	16
49	Efficacy and safety of triple versus dual combination blood pressure-lowering drug therapy: a systematic review and meta-analysis of randomized controlled trials. <i>Journal of Hypertension</i> , <b>2019</b> , 37, 1567-1573	1.9	27
48	eHealth Tools to Provide Structured Assistance for Atrial Fibrillation Screening, Management, and Guideline-Recommended Therapy in Metropolitan General Practice: The AF - SMART Study. <i>Journal of the American Heart Association</i> , <b>2019</b> , 8, e010959	6	29
47	Barriers and Facilitators to the Use of Cardiovascular Fixed-Dose Combination Medication (Polypills) in Andhra Pradesh, India: A Mixed-Methods Study. <i>Global Heart</i> , <b>2019</b> , 14, 303-310	2.9	5
46	Gaps in Guidelines for the Management of Diabetes in Low- and Middle-Income Versus High-Income Countries-A Systematic Review. <i>Diabetes Care</i> , <b>2018</b> , 41, 1097-1105	14.6	44
45	Polypills for the secondary prevention of cardiovascular disease: effective in improving adherence but are they safe?. <i>Therapeutic Advances in Drug Safety</i> , <b>2018</b> , 9, 157-162	3.5	8
44	Considering pharmacy workflow in the context of Australian community pharmacy: A pilot time and motion study. <i>Research in Social and Administrative Pharmacy</i> , <b>2018</b> , 14, 1157-1162	2.9	8
43	Fixed Low-Dose Triple Combination Antihypertensive Medication vs Usual Care for Blood Pressure Control in Patients With Mild to Moderate Hypertension in Sri Lanka: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2018</b> , 320, 566-579	27.4	76
42	Atrial Fibrillation Screen, Management And Guideline Recommended Therapy (AF SMART II) in the rural primary care setting: an implementation study protocol. <i>BMJ Open</i> , <b>2018</b> , 8, e023130	3	11
41	Process evaluation of a randomised controlled trial of a pharmacological strategy to improve hypertension control: protocol for a qualitative study. <i>BMJ Open</i> , <b>2018</b> , 8, e022317	3	1
40	Putting polypills into practice: challenges and lessons learned. <i>Lancet, The</i> , <b>2017</b> , 389, 1066-1074	40	45
39	Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review. <i>Lancet, The</i> , <b>2017</b> , 389, 1035-1042	40	71
38	Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk. <i>European Journal of Preventive Cardiology</i> , <b>2017</b> , 24, 951-961	3.9	15
37	Impact of switching to polypill based therapy by baseline potency of medication: Post-hoc analysis of the SPACE Collaboration dataset. <i>International Journal of Cardiology</i> , <b>2017</b> , 249, 443-447	3.2	2
36	Protocol changes to the TRIUMPH study. <i>American Heart Journal</i> , <b>2017</b> , 191, e1	4.9	3
35	Healthcare expenditure on Indigenous and non-Indigenous Australians at high risk of cardiovascular disease. <i>International Journal for Equity in Health</i> , <b>2017</b> , 16, 108	4.6	4
34	Innovative Approaches to Hypertension Control in Low- and Middle-Income Countries. <i>Cardiology Clinics</i> , <b>2017</b> , 35, 99-115	2.5	40

33	Efficacy and Safety of Quarter-Dose Blood Pressure-Lowering Agents: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Hypertension</i> , <b>2017</b> , 70, 85-93	8.5	27
32	PS 14-28 EFFICACY AND SAFETY OF COMBINATION OF THREE OR MORE BP LOWERING DRUGS FOR THE MANAGEMENT OF HIGH BLOOD PRESSURE. <i>Journal of Hypertension</i> , <b>2016</b> , 34, e442	1.9	
31	Polypill treatments for cardiovascular diseases. <i>Expert Opinion on Drug Delivery</i> , <b>2016</b> , 13, 1-6	8	31
30	Estimated cardiovascular relative risk reduction from fixed-dose combination pill (polypill) treatment in a wide range of patients with a moderate risk of cardiovascular disease. <i>European Journal of Preventive Cardiology</i> , <b>2016</b> , 23, 1289-97	3.9	11
29	Do polypills lead to neglect of lifestyle risk factors? Findings from an individual participant data meta-analysis among 3140 patients at high risk of cardiovascular disease. <i>European Journal of Preventive Cardiology</i> , <b>2016</b> , 23, 1393-400	3.9	12
28	Effectiveness of fixed dose combination medication ('polypills') compared with usual care in patients with cardiovascular disease or at high risk: A prospective, individual patient data meta-analysis of 3140 patients in six countries. <i>International Journal of Cardiology</i> , <b>2016</b> , 205, 147-156	3.2	77
27	An integrated general practice and pharmacy-based intervention to promote the use of appropriate preventive medications among individuals at high cardiovascular disease risk: protocol for a cluster randomized controlled trial. <i>Implementation Science</i> , <b>2016</b> , 11, 129	8.4	7
26	Risks associated with permanent discontinuation of blood pressure-lowering medications in patients with type 2 diabetes. <i>Journal of Hypertension</i> , <b>2016</b> , 34, 781-7	1.9	30
25	Interventions to improve medication adherence in coronary disease patients: A systematic review and meta-analysis of randomised controlled trials. <i>European Journal of Preventive Cardiology</i> , <b>2016</b> , 23, 1065-76	3.9	35
24	Polypill: Progress and Challenges to Global Use--Update on the Trials and Policy Implementation. <i>Current Cardiology Reports</i> , <b>2015</b> , 17, 121	4.2	8
23	Comparison of a morning polypill, evening polypill and individual pills on LDL-cholesterol, ambulatory blood pressure and adherence in high-risk patients; a randomized crossover trial. <i>International Journal of Cardiology</i> , <b>2015</b> , 181, 193-9	3.2	32
22	A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. <i>European Journal of Preventive Cardiology</i> , <b>2015</b> , 22, 920-30	3.9	98
21	Behaviour change strategies for reducing blood pressure-related disease burden: findings from a global implementation research programme. <i>Implementation Science</i> , <b>2015</b> , 10, 158	8.4	22
20	The Effect of a Cardiovascular Polypill Strategy on Pill Burden. <i>Cardiovascular Therapeutics</i> , <b>2015</b> , 33, 347-52	3.3	20
19	TRiple pill vs Usual care Management for Patients with mild-to-moderate Hypertension (TRIUMPH): Study protocol. <i>American Heart Journal</i> , <b>2014</b> , 167, 127-32	4.9	12
18	Prevention: coronary artery calcium and polypill therapy. <i>Nature Reviews Cardiology</i> , <b>2014</b> , 11, 7-8	14.8	3
17	Reply: Personalization of therapy and polypills. <i>Nature Reviews Cardiology</i> , <b>2014</b> , 11, 307	14.8	
16	The association between resting heart rate, cardiovascular disease and mortality: evidence from 112,680 men and women in 12 cohorts. <i>European Journal of Preventive Cardiology</i> , <b>2014</b> , 21, 719-26	3.9	67

15	An economic case for a cardiovascular polypill? A cost analysis of the Kanyini GAP trial. <i>Medical Journal of Australia</i> , <b>2014</b> , 201, 671-3	4	12
14	The evening versus morning polypill utilization study: the TEMPUS rationale and design. <i>European Journal of Preventive Cardiology</i> , <b>2014</b> , 21, 425-33	3.9	8
13	The polypill in the prevention of cardiovascular disease. <i>Australian Prescriber</i> , <b>2014</b> , 37, 82-86	1.4	2
12	Prospective meta-analysis of trials comparing fixed dose combination based care with usual care in individuals at high cardiovascular risk: the SPACE Collaboration. <i>International Journal of Cardiology</i> , <b>2013</b> , 170, 30-5	3.2	23
11	Resting heart rate and the risk of death and cardiovascular complications in patients with type 2 diabetes mellitus. <i>Diabetologia</i> , <b>2012</b> , 55, 1283-90	10.3	73
10	The cardiovascular polypill in high-risk patients. <i>European Journal of Preventive Cardiology</i> , <b>2012</b> , 19, 1234-42	3.9	20
9	The efficacy and tolerability of 'polypills': meta-analysis of randomised controlled trials. <i>PLoS ONE</i> , <b>2012</b> , 7, e52145	3.7	54
8	An international randomised placebo-controlled trial of a four-component combination pill ("polypill") in people with raised cardiovascular risk. <i>PLoS ONE</i> , <b>2011</b> , 6, e19857	3.7	93
7	Perceptions of risk: understanding cardiovascular disease. <i>Risk Management and Healthcare Policy</i> , <b>2010</b> , 3, 49-60	2.8	70
6	Effects of internet-based tailored advice on the use of cholesterol-lowering interventions: a randomized controlled trial. <i>Journal of Medical Internet Research</i> , <b>2010</b> , 12, e42	7.6	11
5	Gaps in cardiovascular disease risk management in Australian general practice. <i>Medical Journal of Australia</i> , <b>2009</b> , 191, 324-9	4	100
4	An electronic clinical decision support tool to assist primary care providers in cardiovascular disease risk management: development and mixed methods evaluation. <i>Journal of Medical Internet Research</i> , <b>2009</b> , 11, e51	7.6	48
3	Palliative care: a public health priority in developing countries. <i>Journal of Public Health Policy</i> , <b>2007</b> , 28, 28-39	2.9	28
2	The use of subcutaneous omeprazole in the treatment of dyspepsia in palliative care patients. <i>Journal of Pain and Symptom Management</i> , <b>2004</b> , 28, 529-31	4.8	19
1	Challenges and opportunities in employing digital health to address self-management needs of people with NCDs in India. <i>BMJ Innovations</i> , bmjinnov-2020-000620	1.8	1